James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present ...

Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study.

Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - - Elion to Present ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Already FDA-approved for adults and children 12 years or older, researchers explore extending the nemolizumab age range down to 2 years in atopic dermatitis.

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo ...

Utility of circulating tumor DNA in patients with resectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal ...

Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral BI 1815368 from Boehringer Ingelheim aims to ...